Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial.
about
Evolving Paradigm of Radiotherapy for High-Risk Prostate Cancer: Current Consensus and Continuing ControversiesProstate Radiotherapy in the Era of Advanced Imaging and Precision MedicineRationale and development of image-guided intensity-modulated radiotherapy post-prostatectomy: the present standard of care?Radiation Therapy Intensification for Solid Tumors: A Systematic Review of Randomized TrialsDuration of androgen suppression before radiotherapy for localized prostate cancer: radiation therapy oncology group randomized clinical trial 9910.Guidance of treatment decisions in risk-adapted primary radiotherapy for prostate cancer using multiparametric magnetic resonance imaging: a single center experience.High dose versus conventional dose in external beam radiotherapy of prostate cancer: a meta-analysis of long-term follow-up.Randomized Phase III Noninferiority Study Comparing Two Radiotherapy Fractionation Schedules in Patients With Low-Risk Prostate Cancer.Symptom clusters for revising scale membership in the analysis of prostate cancer patient reported outcome measures: a secondary data analysis of the Medical Research Council RT01 trial (ISCRTN47772397).Stereotactic Body Radiotherapy for Clinically Localized Prostate Cancer: Toxicity and Biochemical Disease-Free Outcomes from a Multi-Institutional Patient Registry.Improved survival with the addition of radiotherapy to androgen deprivation: questions answered and a review of current controversies in radiotherapy for non-metastatic prostate cancer.Can we avoid dose escalation for intermediate-risk prostate cancer in the setting of short-course neoadjuvant androgen deprivation?Hypofractionated intensity-modulated radiotherapy in patients with localized prostate cancer: a preliminary study.Common genetic variation associated with increased susceptibility to prostate cancer does not increase risk of radiotherapy toxicity.Can we avoid high levels of dose escalation for high-risk prostate cancer in the setting of androgen deprivation?Different outcomes among favourable and unfavourable intermediate-risk prostate cancer patients treated with hypofractionated radiotherapy and androgen deprivation therapy.Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trialRadiotherapy and Hormone Treatment in Prostate CancerVery High-Risk Localized Prostate Cancer: Outcomes Following Definitive Radiation.Supplementary searches of PubMed to improve currency of MEDLINE and MEDLINE In-Process searches via Ovid.Prostate Cancer Radiation Therapy: What Do Clinicians Have to Know?Toxicity and quality of life report of a phase II study of stereotactic body radiotherapy (SBRT) for low and intermediate risk prostate cancer.Comparison of dosimetric parameters and acute toxicity after whole-pelvic vs prostate-only volumetric-modulated arc therapy with daily image guidance for prostate cancer.Rectal/urinary toxicity after hypofractionated vs conventional radiotherapy in low/intermediate risk localized prostate cancer: systematic review and meta analysis.Potential applications of image-guided radiotherapy for radiation dose escalation in patients with early stage high-risk prostate cancer.Radiotherapy for high-risk prostate cancer.Effect of androgen deprivation therapy on intraprostatic tumour volume identified on 18F choline PET/CT for prostate dose painting radiotherapy.Prostate cancer radiotherapy: potential applications of metal nanoparticles for imaging and therapy.Delivered dose can be a better predictor of rectal toxicity than planned dose in prostate radiotherapy.The delineation of intraprostatic boost regions for radiotherapy using multimodality imaging.Accumulated dose to the rectum, measured using dose-volume histograms and dose-surface maps, is different from planned dose in all patients treated with radiotherapy for prostate cancerImage-guided radiotherapy for prostate cancer in the United Kingdom: a national survey.The Role of Hypofractionated Radiotherapy in Prostate Cancer.Ion therapy of prostate cancer: daily rectal dose reduction by application of spacer gel.Weighing Risk of Cardiovascular Mortality Against Potential Benefit of Hormonal Therapy in Intermediate-Risk Prostate Cancer.[No evidence for improved outcome with salvage radiotherapy for asymptomatic biochemical prostate cancer recurrence after prostatectomy by additive androgen suppression].Consensus and differences in primary radiotherapy for localized and locally advanced prostate cancer in Switzerland: A survey on patterns of practice.Targeting MicroRNAs in Prostate Cancer Radiotherapy.Intensity-modulated radiation therapy from 70Gy to 80Gy in prostate cancer: six- year outcomes and predictors of late toxicity.A comparative assessment of prostate positioning guided by three-dimensional ultrasound and cone beam CT.
P2860
Q26744606-47E604FB-61A7-46AD-8153-B1B7A07AFF02Q26749961-2DDF1B2C-1795-4004-8614-DF651107295AQ26774847-34D8ABAF-5C6C-4115-8CA7-D461BBF0352FQ30278410-191B9CBC-F2F7-42AB-B337-A2DBABCE47ADQ34996654-1711F186-46D1-42B5-84FE-6948CDCFD037Q35131928-AB68948A-A250-4AF7-B512-E700FECFD49BQ35235550-6DB9513C-12A4-4B6C-9FF4-821793453B34Q35979481-83D5F456-DD37-468C-964F-60A135F3414AQ36326326-D946ADA4-529D-4630-8AEA-0C18913C3246Q36426682-D0A87DD1-AE56-439B-A2FC-CC328F123BC1Q36474222-1EC8263A-1B3F-4C7A-A929-9E2867310004Q36726123-F98BFF9B-72B7-4CCB-AC7D-EC59C2E139E5Q36798868-B851CB26-79EC-4DF5-92BD-21655F54427CQ36898448-D587A053-9179-407F-9611-A1F5A260E262Q36908059-ADB2C427-1C63-4707-B220-E6467818821DQ36982057-C533F647-FEE8-4BD7-9142-5E2F190943E9Q37128114-14A01106-876E-4C41-93F7-60868F7EC950Q37176612-5EF5427D-08A3-43D0-9182-FBBF7E9F5A5EQ37342181-EAE57B7D-BC9E-4AE7-BF6E-B815CBE6901CQ37365243-9C1C23A7-C945-4C4F-BB81-444AE148D736Q37578562-B71CE54A-20D9-4D75-AD37-DA238ED0B7A8Q37586877-7C169786-ED11-4F0D-A80E-ADB7704B828DQ37601093-918C5B65-BFC7-48E5-A3F8-85307EC95019Q37725623-05A649FB-6755-474F-B6F4-A95E180E2533Q38362692-AB00BF77-72C9-4573-8D1A-9BA1454D2ED5Q38364578-770698AE-DD66-417E-A846-20905A298AB0Q38403763-DF27CC33-B92A-4D78-AAAC-D27E5A282028Q38519540-DBB52607-8747-41BF-9EC0-F082E89A5B9EQ38810620-95F3DC2D-D235-45AC-A04F-01ACA9E0C97FQ38851017-7136D2CD-E0A2-49AB-89D7-F90198D84262Q38981805-8CCF5779-0F3A-416F-86C5-2E7E51E09745Q39124431-193746AB-BDE1-473E-B811-4B5B5F9C0E00Q39200876-CB0D270B-0C95-4963-BA66-FB1377DFC42DQ39701751-286351D9-7A4F-40C4-A2A6-33C25E53E899Q40400351-B6CBEE4A-EB7F-41C6-AEA3-C59C7A36FC16Q40447684-CAE79162-2D69-4A4C-926D-6AF747EEA8BFQ40927190-B0873F42-8D18-44B9-B03C-CC04B2DCD2D2Q41239908-3AAB81E6-5012-4655-8547-A3BF32DC5534Q42199585-80BF12BD-FEE3-452D-B7DC-F0D211FEFBC1Q42491394-5F435A54-140F-455B-9CAB-D6E87388B317
P2860
Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
Escalated-dose versus control- ...... 1 randomised controlled trial.
@en
Escalated-dose versus control- ...... 1 randomised controlled trial.
@nl
type
label
Escalated-dose versus control- ...... 1 randomised controlled trial.
@en
Escalated-dose versus control- ...... 1 randomised controlled trial.
@nl
prefLabel
Escalated-dose versus control- ...... 1 randomised controlled trial.
@en
Escalated-dose versus control- ...... 1 randomised controlled trial.
@nl
P2093
P50
P1433
P1476
Escalated-dose versus control- ...... 1 randomised controlled trial.
@en
P2093
Chakiath C Jose
Christopher D Scrase
Claire Murphy
David Bottomley
David P Dearnaley
Edwin G Aird
Gordana Jovic
Isabel Syndikus
J Martin Russell
John H L Matthews
P304
P356
10.1016/S1470-2045(14)70040-3
P577
2014-02-26T00:00:00Z